Nanjing Cellnuo Biopharmaceutical

Nanjing-based biopharmaceutical company making insulin analogues and metabolic peptide APIs by genetic engineering, and offering technology transfer to drug manufacturers. Holds active US Drug Master Files for retatrutide, semaglutide and tirzepatide API. No FDA inspection is on record.

Directory assessment: Nanjing Cellnuo Biopharmaceutical is listed as a manufacturer in the peptide supply chain, serving Asia markets from China (Nanjing). As a direct manufacturer, this supplier controls its own production process from synthesis through purification and quality control release testing. This profile lists 2 sources for reference. This supplier has a medium confidence score — verification signals are present, but the listing is newer or less documented; perform standard due diligence before engaging.